Cytological findings of ROS1‐rearranged lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23845
Abstract: ROS1‐rearranged lung adenocarcinoma has been recently identified. We report a case of ROS1‐rearranged lung adenocarcinoma with special emphasis on cytological findings. Here, we report a case of young woman with ROS1‐rearranged lung adenocarcinoma diagnosed by… read more here.
Keywords: lung adenocarcinoma; cytological findings; rearranged lung; ros1 rearranged ... See more keywords
Cytological features in eight patients with ALK‐rearranged lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23879
Abstract: ALK‐rearranged lung cancer has been recently identified. Although signet‐ring cell morphology and mucinous cribriform pattern are considered to be characteristic of ALK‐rearranged lung cancer. Some studies have also suggested cytological features. read more here.
Keywords: alk rearranged; rearranged lung; cytological features; lung cancer ... See more keywords
Lorlatinib in ALK-Rearranged Lung Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer cell"
DOI: 10.1016/j.ccell.2020.12.017
Abstract: Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with… read more here.
Keywords: lorlatinib alk; lung cancer; cancer; alk rearranged ... See more keywords
A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13496
Abstract: Reports of crizotinib‐induced pleural effusion in non‐small cell lung cancer (NSCLC) are limited. A 35‐year‐old Japanese woman was diagnosed with ROS1‐rearranged lung adenocarcinoma (primary left lower lobe, cT4N3M1c). Crizotinib was administered as first‐line therapy, and… read more here.
Keywords: lung adenocarcinoma; crizotinib; pleural effusion; effusion ... See more keywords
Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15579
Abstract: Lorlatinib, a third‐generation anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitor (TKI) with a broad coverage against ALK mutations, has demonstrated dramatic effects in patients with ALK‐rearranged lung cancer. The mechanisms of acquired resistance to lorlatinib by… read more here.
Keywords: lung cancer; alk rearranged; rearranged lung; resistance ... See more keywords
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-18-0325
Abstract: The mechanisms responsible for the development of resistance to alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, are still unclear, and few cell lines are currently available for investigating ALK-rearranged lung cancer. To identify the… read more here.
Keywords: alk; alk rearranged; resistance; cancer ... See more keywords
Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Internal Medicine"
DOI: 10.2169/internalmedicine.1982-18
Abstract: Hypertrophic pulmonary osteoarthropathy (HPO) is a paraneoplastic syndrome characterized by digital clubbing, arthritis, and periostitis. Tumor removal usually leads to the resolution of these symptoms. We herein report the efficacy of crizotinib treatment for treating… read more here.
Keywords: rearranged lung; treatment; crizotinib; ros1 rearranged ... See more keywords